Document:

Exhibit 10.10

                                LICENSE AGREEMENT

         THIS LICENSE AGREEMENT ("Agreement") is entered into as of the 6th day
of July, 2001, (the "Effective Date") by and between CS Medical Technologies,
LLC, a Delaware limited liability company ("CS Medical") and Pro Uro Care Inc.,
a Minnesota corporation ("Licensee").

                                    RECITALS

         WHEREAS, CS Medical owns or has licensed the Licensed Technology
(defined below); and

         WHEREAS, the parties desire for Licensee to be granted an exclusive
license to the Licensed Technology in the defined field of use, subject to the
terms and conditions of this Agreement.

         NOW THEREFORE, in consideration of the foregoing and the covenants and
premises contained in this Agreement, the parties agree as follows:

                                    ARTICLE 1
                                   DEFINITIONS

         As used herein, capitalized terms will have the meanings set forth
below.

         1.1 "Affiliate" shall mean any entity that controls, is controlled by
or is under common control with a party hereto. "Control" shall mean the
possession of the power to direct or cause the direction of the management and
policies of such entity, whether through the ownership of voting securities, by
contract or otherwise.

         1.2 "Confidential Information" shall mean any confidential or
proprietary information embodied in the Devices or Licensed Technology, and any
information which relates to any research project, work in process, future
development, scientific, engineering, manufacturing, marketing, business plan,
financial or personnel matter relating to either party, its present or future
products, sales, suppliers, customers, employees, investors or business, whether
in oral, written, graphic or electronic form.

         1.3 "Devices" shall mean any composition of matter, material or product
that is either covered by the Licensed Patents or the Licensed Know-how, or
whose manufacture, use or sale would constitute, but for the license granted to
Licensee pursuant to this agreement, an infringement of any pending or issued
claim within the Patent Rights.

         1.4 "Field of Use" shall mean the treatment of (a) benign prostatic
hyperplasia; (b) prostatitis; (c) prostate cancer; or (d) any other conditions
of urologic disorder which may be diagnosed, imaged or treated using a
catheter-based microwave technology or sensor imaging systems.
<PAGE>

         1.5 "Licensed Know-how" means all techniques, inventions, practices,
methods, knowledge, skill, experience, bench testing information, and all other
information and data relating to the Licensed Patents or the Field of Use, and
which are now or in the future owned or licensed, with a right of sublicense, by
CS Medical or its Affiliates.

         1.6 "Licensed Patents" means (a) the patents and patent applications
listed on Exhibit A hereto, (b) any future patents and patent applications
pertaining to or that have application in the Field of Use, and which are owned
or licensed, with a right of sublicense, by CS Medical or its Affiliates, and
(c) all foreign counterparts, all substitutions, extensions, reissues, renewals,
continuations and continuations in part relating to any Licensed Patents and
their foreign counterparts, and which are owned or licensed, with a right of
sublicense, by CS Medical or its Affiliates. Exhibit A shall be updated by the
parties as needed from time to time during the term of this Agreement.

         1.7 "Licensed Technology" means (a) the inventions, discoveries,
processes, devices and/or claims covered under the Licensed Patents; and (b) the
Licensed Know-how.

         1.8 "Net Sales" means all revenues recognized in accordance with
generally accepted accounting principles relating to the sale of Devices by or
for Licensee, less transportation charges, discounts actually taken, credits
allowed for defective or returned goods, and other allowances (actually paid or
allowed, including but not limited to, prompt payment and volume discounts,
charge backs from wholesalers and other allowances granted to the end commercial
customer of the Devices, whether in cash or trade), insurance and sales and
other taxes based on sales prices when included in gross sales, but not
including taxes assessed on income derived from such sales.

                                    ARTICLE 2
                     GRANT OF LICENSE AND OTHER OBLIGATIONS

         2.1 License Grant. Subject to the terms and conditions of this
Agreement, CS Medical hereby grants to Licensee an exclusive, worldwide,
royalty-bearing, limited license under the Licensed Technology to make, have
made, import, use, sell and have sold the Devices solely within the Field of
Use.

         2.2 Degree of Exclusivity. Except as otherwise provided herein, the
license granted in Section 2.1 shall be exclusive for the life of the Agreement.
As used herein, "exclusive" shall mean that CS Medical may not grant any other
license to any other third party of the Licensed Technology, in whole or in
part, and may not itself practice any claim encompassed within the foregoing on
a commercial basis within the Field of Use. Notwithstanding the foregoing, CS
Medical and its Affiliates may use any of the Licensed Technology solely and
exclusively for their own internal and noncommercial research and development
purposes within the Field of Use, and CS Medical and other third parties reserve
the right to make, to have made, use or sell, directly or through others, for
any products embodying or otherwise using the Licensed Technology for
applications outside the Field of Use.

                                       2
<PAGE>

         2.3 No Trademark License. Subject to Section 5.4 below with respect to
patent markings, nothing contained in this Agreement shall be construed as
conferring any right to Licensee to use in its advertising, publicity, or other
promotional activities any name, trade name, trademark, or other designation of
CS Medical or its licensors.

         2.4 Sublicense. Licensee may grant to third parties a sublicense to
manufacture, use, import or sell Devices developed by Licensee, provided that a
least a majority of the members of Licensees Board of Directors approves such
sublicense. Licensee may grant to third parties a sublicense to manufacture,
use, import or sell Devices not developed by Licensee, provided that (a) CS
Medical preapproves in writing such sublicense, and (b) CS Medical and Licensee
agree in writing upon the royalties payable to CS Medical as a result of such
sublicense.

         2.5 Services of Ray Kasevich. As of the Effective Date, an Affiliate of
CS Medical employs Ray Kasevich. Provided that Ray Kasevich continues to be
employed by CS Medical or an Affiliate, CS Medical agrees that it will make the
services of Ray Kasevich available to Licensee on a part-time basis
(approximately 10%) pursuant to a separate agreement, as either a consultant or
an employee, with Licensee to be responsible for paying the amounts (e.g.,
salary and benefits) earned by Mr. Kasevich through such arrangement, and
provided that Mr. Kasevich consents to such arrangement.

         2.6 Certain Items. CS Medical will make available to Licensee for its
use (or benefit as described below) certain leased equipment and a microwave
generator prototype, which are relevant to the Licensed Technology in the Field
of Use. Licensee agrees to pay to CS Medical a pro rata share of one-third (33%)
of the monthly lease expenses for such leased equipment promptly when invoiced,
and acknowledges that such leased equipment will be (a) used by Ray Kasevich in
the performance of the services for Licensee as described in Section 2.5, (b)
continue to also be used by CS Medical and its Affiliates in their business, and
(c) will remain at the physical location(s) selected by CS Medical. As of the
Effective Date, the microwave generator prototype (a) will be located at CS
Medical's facilities but may be relocated at Licensee's request and expense at a
later time, (b) may be used by Licensee only in furtherance of the development
of the Devices as contemplated hereunder, (c) will be maintained by Licensee at
its expense when in its possession or control, and (d) will be promptly returned
to CS Medical upon any termination of this Agreement. As between the parties, CS
Medical will retain all right, title and interest in and to the leased equipment
and microwave generator prototype, and Licensee shall only have the limited
right to use such items as described herein.

         2.7 Licensed Know-how. CS Medical will provide or make available all
Licensed Know-how to Licensee in a timely manner.

                                    ARTICLE 3
                                    OWNERSHIP

         Licensee acknowledges and agrees that, as between CS Medical and
Licensee, CS Medical shall retain all rights to the Licensed Technology, and
Licensee shall have no rights in the Licensed Technology other than those rights
expressly granted to Licensee under this Agreement.

                                       3
<PAGE>

                                    ARTICLE 4
                                  CONSIDERATION

         4.1 Calculation and Payment of Royalties. Beginning on the Effective
Date, Licensee shall pay to CS Medical an ongoing royalty pursuant to this
Section 4.1.

                  (a) Calculation of Royalties. Within thirty (30) days after
the end of each calendar quarter, Licensee shall pay to CS Medical a royalty of
one-half percent (0.5%) of the amount by which Net Sales of all Devices sold or
distributed during such calendar quarter exceeds $500,000.

                  (b) Payment of Royalties. At the same time that it makes
payments of royalties due with respect to a calendar quarter, Licensee shall
deliver to CS Medical a true and complete accounting of sales of Devices and
receipts from those sales during the quarter, with a separate accounting of
sales and receipts by country and a calculation of the royalty payment due CS
Medical for such calendar quarter. If no sales of Devices were made in such
quarter, then Licensee's statement shall be a statement to such effect. Licensee
hereby covenants that if it desires to sell, lease or otherwise place any
Devices in exchange for consideration in a manner that makes it impractical to
calculate the royalty due, it will not do so without first devising a mechanism
for the calculation of royalties thereon and obtaining CS Medical's prior
written consent for such mechanism.

         4.2 Foreign Payments. In transactions giving rise to an obligation to
make payment hereunder with respect to which Licensee receives payment in a
currency other than U.S. Dollars, all payments required to be made by Licensee
under Section 4.1 shall be converted, prior to payment, into U.S. Dollars at the
applicable rate of exchange of Citibank, N.A., in New York, New York, on the
last day of the calendar quarter in which such transaction occurred. If Licensee
is prevented from making any payment under this Agreement by virtue of the laws
of the country from which the payment is to be made, Licensee may deposit the
amount that has accrued to CS Medical's account in the currency of such country
in a bank in such country that is acceptable to CS Medical.

         4.3 Overdue Payments. Payments due to CS Medical hereunder shall, if
not paid when due under the terms of this Agreement, bear simple interest at the
lesser of 1.5% per month or the highest rate permitted by law, calculated on the
basis of a 360-day year for the number of days actually elapsed, beginning on
the due date and ending on the day prior to the day on which payment is made in
full. Interest accruing under this Section shall be due to CS Medical on demand.
The accrual or receipt by CS Medical of interest under this Section shall not
constitute a waiver by CS Medical of any right it may otherwise have to declare
a default under this Agreement or to terminate this Agreement.

                                    ARTICLE 5
                                OTHER OBLIGATIONS

         5.1 Licensee Responsibility. Licensee shall diligently proceed with the
development, manufacture, and sale of Devices within the Field of Use and shall
earnestly and diligently endeavor to market the same within a reasonable time
after execution of this Agreement and in quantities sufficient to meet the
market demands therefor.

                                       4
<PAGE>

         5.2 Government Approvals. As between the parties, Licensee shall be
solely obligated to obtain all necessary governmental approvals for the
manufacture, use, and sale of Devices within the Field of Use in the United
States or any other countries.

         5.3 Progress Reports. Beginning at the end of the first anniversary of
the Effective Date and annually thereafter, Licensee shall submit to CS Medical
a summary progress report covering Licensee's activities in the preceding year
related to the development and testing of all Devices within the Field of Use
and Licensee's progress, if any, in obtaining governmental approvals necessary
for marketing such products. * Such progress reports shall include, but not be
limited to, a summary of the following topics: research and development work
completed; key scientific discoveries; work in progress; current schedule of
anticipated events or milestones; and market plans for introduction of new or
additional Devices.

         5.4 Patent Marking. Licensee shall mark all Devices made, used, or sold
under the terms of this Agreement, or their containers, in accordance with 35
U.S.C. ss. 287(a) or any other successor statute in the United States and the
applicable patent marking laws of any other country. Upon CS Medical' written
request, Licensee shall furnish reasonable and representative samples of the
Devices to demonstrate compliance with this Section.

         5.5 Insurance. Licensee, at its sole cost and expense, shall insure its
activities in connection with the exercise of its license under this Agreement
in an appropriate amount at all times. Without limiting the foregoing, Licensee
shall obtain, keep in force, and maintain, at a minimum, Comprehensive or
Commercial Form General Liability Insurance (contractual liability included) or
an equivalent program of self-insurance with appropriate limits, which limits
will increase as needed depending on the activities of Licensee (i.e., more
coverage once human testing begins).

                                    ARTICLE 6
                                 CONFIDENTIALITY

         6.1 Confidentiality. During the term of this Agreement and thereafter,
each party hereto will maintain in confidence all Confidential Information
disclosed by the other party hereto. Neither party will use, disclose or grant
use of such Confidential Information except as expressly authorized by this
Agreement. To the extent that disclosure is authorized by this Agreement, the
disclosing party will obtain prior agreement from its employees, agents or
consultants to whom disclosure is to be made to hold in confidence and not make
use of such information for any purpose other than those permitted by this
Agreement. Each party will use at least the same standard of care as it uses to
protect its own Confidential Information to ensure that such employees, agents
or consultants do not disclose or make any unauthorized use of such Confidential
Information. Each party will promptly notify the other upon discovery of any
unauthorized use or disclosure of the Confidential Information.

                                       5
<PAGE>

         6.2 Exceptions. The obligations of confidentiality contained in Section
6.1 will not apply to the extent that it can be established by the receiving
party by competent written proof that such Confidential Information:

         (a) was already known to the receiving party, other than under an
obligation of confidentiality, at the time of disclosure by the other party;

         (b) was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the other party;

         (c) became generally available to the public or otherwise part of the
public domain after its disclosure and other than through any act or omission of
the receiving party in breach of this Agreement;

         (d) was disclosed to the receiving party, other than under an
obligation of confidentiality, by a third party who had no obligation to the
other party not to disclose such information to others.

The parties agree that the material financial terms of this Agreement will also
be considered Confidential Information of both parties.

         6.3 Authorized Disclosure. Each party may disclose the Confidential
Information to the extent such disclosure is reasonably necessary in complying
with applicable governmental regulations, provided that if such party is
required to make any such disclosure of the Confidential Information it will to
the extent practicable give reasonable advance notice to the other party of such
disclosure requirement so that confidential treatment of the information
required to be disclosed may be secured.

                                    ARTICLE 7
                                TERM; TERMINATION

         7.1 Term. This Agreement will commence on the Effective Date and,
unless sooner terminated as provided hereunder, will terminate upon the
expiration of the last to expire patent included in the Licensed Technology.

         7.2 Termination by CS Medical. CS Medical may terminate this Agreement
in accordance with the following:

                  (a) Failure to Make Timely Payment. CS Medical may terminate
this Agreement upon ten (10) days written notice if Licensee fails to timely
make any payment required by this Agreement and fails to cure the nonpayment
within ten (10) days of written notice thereof from Licensee.

                  (b) Failure to Capitalize. CS Medical may terminate this
Agreement upon thirty (30) days written notice to Licensee, unless on or before
December 31, 2002, CS Medical has received a certificate signed by at least a
majority of the Board of Directors of Licensee indicating that Licensee has
obtained at least $1,000,000.00 in new capital investment on or before the date
of such certificate. In this connection, it is understood that Licensee may
obtain this capital investment either through direct investments by investors,
or through a merger or other form of acquisition or business combination, which
results in at least $1,000,000.00 being available for development and other
activities undertaken in connection with this Agreement.

                                       6
<PAGE>

         7.3 Termination by Either Party. This Agreement may be terminated by
either party upon written notice if the other party breaches a material
provision of this Agreement and does not cure such breach within sixty (60) days
of written notice thereof.

         7.4      Effect of Termination.

                  (a) Termination of License. Upon termination or expiration of
this Agreement for any reason, the license granted to Licensee pursuant to
Section 2.1 shall automatically terminate. Licensee shall immediately cease all
use of the Licensed Technology, including all Licensed Technology included in
the Devices, and shall provide a written account to CS Medical of the following
within fifteen (15) days of termination:

                       (1) All development in progress; sales of Devices
                           made but not shipped; inventory of Devices on hand as
                           well as work in process;

                       (2) Royalties due but not paid up to date of
                           termination.

                  (b) Return of Confidential Information. Within thirty (30)
days of termination of this Agreement for any reason, both parties shall return
or destroy all copies of the other party's Confidential Information and shall
provide written certification of such destruction upon request of the other
party.

                  (c) Royalty Obligation. Licensee acknowledges that the
termination of this Agreement by either party for any reason shall not absolve
Licensee of its payment and other obligations under Section 4.1(b).

                  (d) - Survival. In the event of termination of this Agreement,
Articles 3, 4, 6, 8, 9,10,11 and 12 shall survive.

                                    ARTICLE 8
                         REPRESENTATIONS AND WARRANTIES

         8.1 Representations and Warranties. Each party hereby represents and
warrants:

         (a) Corporate Power. Such party is duly organized and validly existing
under the laws of the state of its incorporation and has full corporate power
and authority to enter into this Agreement and to carry out the provisions
hereof.

         (b) Due Authorization. Such party is duly authorized to execute and
deliver this Agreement and to perform its obligations hereunder.

                                       7
<PAGE>

         (c) Binding Agreement. This Agreement is a legal and valid obligation
binding upon it and enforceable in accordance with its terms. The execution,
delivery and performance of this Agreement by such party does not conflict with
any agreement, instrument or understanding, oral or written, to which it is a
party or by which it may be bound, nor violate any law or regulation of any
court, governmental body or administrative or other agency having jurisdiction
over it.

         8.2 Representations and Warranties of Licensee. Licensee hereby
represents and warrants to CS Medical the following:

                  (a) Diligent Development and Commercialization. Upon the
obtaining of the capital referred to in Section 7.2(b) hereof, Licensee and its
permitted sublicensees will be diligent in development and commercializing the
Devices, which shall include, without limitation, the continued development of
such Devices, making the necessary filings and applications to appropriate
governmental authorities and undertaking marketing and sales activities.

                  (b) Performance; Noninfringement. Licensee hereby represents
and warrants to CS Medical that it will perform its obligations hereunder in a
lawful, businesslike and professional manner and that, to the knowledge of
Licensee, the Devices do not infringe on any patent, copyright or trade secret
of a third party.

         8.3 Representations and Warranties of CS Medical. CS Medical hereby
represents and warrants to Licensee the following:

                  (a) Right to Grant License. CS Medical, to its knowledge, has
all rights necessary to grant the license hereunder to Licensee.

                  (b) No Infringement Claims. As of the Effective Date, to the
knowledge of CS Medical there are no claims that the Licensed Technology
infringes any patent, copyright or trade secret of a third party.

                  (c) Licensed Technology. To the knowledge of CS Medical, the
Licensed Technology includes all inventions, discoveries, processes, devices
and/or claims covered under patents, and all know-how, which CS Medical or its
Affiliates own or have the right to sublicense for use in the Field of Use.

                                    ARTICLE 9
                    INDEMNIFICATION, LIABILITY, INFRINGEMENT

         9.1 Indemnification by Licensee. Licensee hereby agrees to indemnify,
defend and hold CS Medical harmless from any third party suit, claim or other
legal action ("Legal Action") that alleges the Devices, or any of them, infringe
any patent, copyright, trade secret, trademark or other proprietary right,
including any reasonable costs or legal fees thereby incurred by CS Medical,
except to the extent CS Medical is required to indemnify and hold harmless
Licensee pursuant to Section 9.2. Licensee shall also indemnify, defend and hold
CS Medical harmless against any Legal Action resulting from or arising out of
Licensee's performance under or breach of this Agreement, including, but not
limited to, any damages, losses or liabilities, whatsoever with respect to death
or injury to any person and damage to any property arising from the design,
possession, manufacture, use, sale, support, servicing or administration of the
Devices. CS Medical shall give Licensee written notice of any Legal Action
within twenty (20) days of CS Medical's first knowledge thereof.

                                       8
<PAGE>

         9.2 Indemnification by CS Medical. CS Medical hereby agrees to
indemnify, defend and hold Licensee harmless from any Legal Action arising out
of or resulting from CS Medical's breach of the warranties contained in Section
8.3, including any reasonable legal fees thereby incurred by Licensee, except to
the extent Licensee is required to indemnify CS Medical under Section 9.1.
Licensee shall give CS Medical written notice of any Legal Action within twenty
(20) days of Licensee's first knowledge thereof.

         9.3 Suit for Infringement by Others. In the event Licensee becomes
aware of any actual or threatened infringement of all or any part of the
Licensed Technology including, without limitation, the patents contained
therein, Licensee shall promptly notify CS Medical and Licensee shall, in its
sole discretion, determine whether to commence infringement proceedings against
the alleged third party infringer. CS Medical shall cooperate in such
proceedings as reasonably requested by Licensee, and at Licensee's expense. If
Licensee does not bring such action within six (6) months from date on which
Licensee notified CS Medical of such infringement, CS Medical may bring such
action at its own expense. If CS Medical commences infringement proceedings,
Licensee shall cooperate in such proceedings, as reasonably requested by CS
Medical, and at CS Medical's expense. In any litigation undertaken by either
party against an accused infringer, neither party shall agree to any settlement,
court order or consent without the other party's written consent to the terms
thereof, which consent will not be unreasonably withheld. The party commencing
litigation against an alleged third party infringer shall be entitled to retain
any and all proceeds from such suit.

                                   ARTICLE 10
              LIMITATION OF LIABILITY AND DISCLAIMER OF WARRANTIES

         10.1 Waiver of Consequential Damages. EXCEPT FOR ANY USE OF THE
LICENSED TECHNOLOGY BY LICENSEE OUTSIDE OF THE SCOPE OF THE LICENSE GRANTED IN
SECTION 2 HEREOF, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR
ANY THIRD PARTY FOR ANY LOST PROFITS, LOST SAVINGS, OR OTHER INCIDENTAL,
SPECIAL, OR CONSEQUENTIAL DAMAGES OR FOR ANY CLAIM BY ANY OTHER PARTY, EVEN IF
SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING OUT OF
OR IN CONNECTION WITH THIS AGREEMENT, THE GRANTING OF THE LICENSE HEREUNDER, OR
THE DESIGN, MANUFACTURE, USE OR SALE OF THE LICENSED TECHNOLOGY OR DEVICES.

         10.2 Disclaimer of Warranties. EXCEPT AS EXPRESSLY PROVIDED HEREIN, CS
MEDICAL IS PROVIDING THE LICENSED TECHNOLOGY AND ANY EQUIPMENT OR OTHER
MATERIALS PROVIDED HEREUNDER "AS IS," AND CS MEDICAL HEREBY EXPRESSLY DISCLAIMS
ANY AND ALL WARRANTIES OF ANY KIND OR NATURE, WHETHER EXPRESS OR IMPLIED,
INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY OR FITNESS FOR
A PARTICULAR PURPOSE, RELATING TO THE LICENSED TECHNOLOGY AND ANY EQUIPMENT OR
OTHER MATERIALS PROVIDED HEREUNDER. Without limiting the generality of the
foregoing, CS Medical expressly does not warrant the accuracy, safety, or
usefulness for any purpose, of the Licensed Technology, any equipment or other
materials provided or made available by CS Medical hereunder or the Devices.
Nothing contained in this Agreement shall be construed as either a warranty or
representation by CS Medical as to the validity or scope of any patents
contained in the Licensed Technology, and CS Medical assumes no liability in
respect of any infringement of any patent or other right of third parties due to
the activities of Licensee or any sublicensee under this Agreement, subject to
Section 8.3(b) above.

                                       9
<PAGE>

                                   ARTICLE 11
                                 RECORDS; AUDIT

         11.1 Records Retention. Licensee will keep complete and accurate
records pertaining to the sale of the Devices. Such records will be maintained
for a three (3) year period following the year in which any such payments were
made hereunder.

         11.2 Audit Request. CS Medical will have the right to engage, at its
own expense, an independent, certified public accountant reasonably acceptable
to Licensee, to examine Licensee's records from time to time as may be necessary
to determine, with respect to any calendar year, the correctness of any report
or payment made under this Agreement. If any such audit reveals an underpayment
of more than five percent (5%) of the correct amount of royalties due hereunder,
such audit will be at the expense of Licensee. If any audit conducted on behalf
of CS Medical shows that Licensee underpaid the royalties due to CS Medical
under the licenses herein as to the period subject to the audit, then Licensee
shall immediately pay to CS Medical any such deficiency with interest thereon at
an annual rate equal to 2% above the U.S. dollar reference rate ("prime rate")
charged from time to time by Citibank, N.A. from the date due until paid or at
such lower rate as shall be the maximum rate permitted by law.

         11.3 Survival. This Article 11 will survive any termination of this
Agreement for a period of three (3) years.

                                   ARTICLE 12
                            MISCELLANEOUS PROVISIONS

         12.1 Entire Agreement. This Agreement (including the Exhibits,
schedules and other documents referred to herein) contains the entire
understanding between the parties with respect to the subject matter hereof and
supersedes any prior understandings, agreements or representations, written or
oral, relating to the subject matter hereof.

         12.2 Counterparts. This Agreement may be executed in separate
counterparts, each of which will be an original and all of which taken together
shall constitute one and the same agreement, and any party hereto may execute
this Agreement by signing any such counterpart.

         12.3 Severability. Whenever possible, each provision of the Agreement
will be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of the Agreement is held to be invalid, illegal or
unenforceable under any applicable law or rule, the validity, legality and
enforceability of the other provision of this Agreement will not be affected or
impaired thereby.

                                       10
<PAGE>

         12.4 Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of the parties hereto and their respective heirs, personal
representatives and, to the extent permitted hereunder, successors and assigns.

         12.5 Assignability. Neither this Agreement nor any right, remedy,
obligation or liability arising hereunder or by reason hereof shall be
assignable (including by operation of law) by Licensee without the prior consent
of at least a majority of the members of Licensee's Board of Directors. Any
assignment which is not in accordance with this Section will be void.

         12.6 Modification, Amendment, Waiver or Termination. No provision of
the Agreement may be modified, amended waived or terminated except by an
instrument in writing signed by the parties to this agreement. No course of
dealing between the parties will modify, amend, waive or terminate any provision
of this Agreement or any rights or obligations of any party under or by reason
of this Agreement.

         12.7 Notices. All notices, consents, requests, instructions, approvals
or other communications provided for herein shall be in writing and delivered by
personal delivery, overnight courier, mail, electronic facsimile or e-mail
addressed to the receiving party at the address set forth herein. All such
communications shall be effective when received.

If to CS MEDICAL:

                  Mr. Alexander Nazarenko
                  CS Medical Technologies, LLC
                  2277 West Highway 36
                  Suite 254
                  Roseville, MN 55113

With a copy to:

                  Frederic F. Hillier
                  Dorsey & Whitney LLP
                  220 South Sixth Street
                  Minneapolis, MN 55402

If to Licensee, addressed to:

                  David Koenig
                  Solar Plastics, Inc.
                  732 30th Avenue S.E.
                  Minneapolis, MN 55414

                                       11
<PAGE>

With a copy to:

                  John Brower
                  Gray Plant Mooty Mooty & Bennett P.A.
                  33 South Sixth Street
                  Suite 3400
                  Minneapolis, MN 55402

Any party may change the address set forth above by notice to each other party
given as provided herein.

         12.8 Headings. The headings contained in this Agreement are for
reference purposes only and shall not in any way affect the meaning or
interpretation of this Agreement.

         12.9 Governing Law. This Agreement is made in accordance with and shall
be governed and construed in accordance with the laws of the State of Minnesota,
without regard to conflicts of laws rules.

                                       12
<PAGE>

         12.10 Third-Party Benefit. Nothing in this Agreement, express or
implied, is intended to confer upon any other person any rights, remedies,
obligations or liabilities of any nature whatsoever.

         12.11 Jurisdiction and Venue. This Agreement may be enforced in any
federal court or state court sitting in Ramsey or Hennepin counties, Minnesota,
and each party consents to the jurisdiction and venue of any such court and
waives any argument that venue in such forum is not convenient. If any party
commences any action under any tort or contract theory arising directly or
indirectly from the relationship created by this Agreement in another
jurisdiction or venue, any other party to this Agreement shall have the option
of transferring the case to the above-described venue or jurisdiction or, if
such transfer cannot be accomplished, to have such case dismissed without
prejudice.

         12.12 Waiver of Jury Trial. Each party irrevocably waives any and all
right to trial by jury in any legal proceeding arising out of or relating to
this agreement or the transactions contemplated hereby.

         12.13 Remedies. The parties agree that money damages may not be an
adequate remedy for any breach of the provisions of this Agreement and that any
party may, in its discretion, apply to any court of law or equity of competent
jurisdiction for specific performance and injunctive relief in order to enforce
or prevent any violations this Agreement, any party against whom such proceeding
is brought hereby waives the claim or defense that such party has an adequate
remedy at law and agrees not to raise the defense that the other party has an
adequate remedy at law.

         12.14 Expenses. Except as otherwise expressly provided for herein, each
party will pay its own expenses (including attorneys' and accountants' fees) in
connection with the negotiation of this Agreement, the performance of its
respective obligations hereunder and the consummation of the transactions
contemplated by this Agreement (whether consummated or not).

         12.15 Advice of Counsel. Each party acknowledges that it has been
advised by counsel in the negotiation, execution and delivery of this Agreement.

         12.16 Relationship of the Parties. Neither party is, nor will be deemed
to be, an agent or legal representative of the other party for any purpose.
Neither party will be entitled to enter into any contracts in the name of or on
behalf of the other party, and neither party will be entitled to pledge the
credit of the other party in any way or hold itself out as having authority to
do so. No party will incur any debts or make any commitments for the other.

         12.17 Force Majeure. Neither party will be liable to the other for loss
or damages or will have any right to terminate this Agreement for any default or
delay (except any default or delay in the payment of money due hereunder)
attributable to any fire, floods, earthquake, embargo, war, act of war (whether
declared or not), insurrections, riots, civil commotions, strikes, lockouts or
other labor disturbances, acts of God or act, omission or delay in acting by any
governmental authority or the other party, if the party affected will give
prompt notice of any such cause to the other party. The party giving such notice
will thereupon be excused from such of its obligations hereunder as it is
thereby disabled from performing for so long as it is so disabled and for thirty
(30) days thereafter; provided, however, that such affected party commences and
continues to take reasonable and diligent actions to cure such cause.

                                       14
<PAGE>

         12.18 Export Control. Licensee acknowledges that the Licensed
Technology and Devices may be subject to the export control laws and regulations
of the United States of America, and it hereby agrees to obey any and all such
laws and regulations. Licensee agrees not to take any actions that would cause
either party to violate the U.S. Foreign Corrupt Practices Act of 1977, as
amended.

                  IN WITNESS WHEREOF, the parties hereto have duly executed this
Agreement, including the Exhibits attached hereto and incorporated herein by
reference.

PRO URO CARE INC.                        CS MEDICAL TECHNOLOGIES, LLC

By: Maurice Taylor                       By: Alex Nazarenko
    ---------------------                    ---------------

Title: President                         Title: Manager
       ------------------                       -------------

                                       15
<PAGE>

                      Exhibit A - List of Licensed Patents

                                   CS MEDICAL

                         SUMMARY OF PATENTS/APPLICATIONS

<TABLE>
<CAPTION>
------------- ---------------- --------------------------------------------- ------------- ---------------------------
Matter        Application      Subject Matter                                Serial No.    Status
Number        Name                                                           Filing Date
------------- ---------------- --------------------------------------------- ------------- ---------------------------
<S>           <C>              <C>                                           <C>            <C>
05785-        Microwave        A medical instrument for                      09/248,165    Issued as U.S. Patent No.
005001        Devices for      providing/withdrawing heat from a target                    6,181,970 on January 30,
              Medical          area (e.g., tumor).                           February 9,   2001
              Hyperthermia,                                                  1999
05785-        Thermotherapy
005WO1        and Diagnosis
              (Microwave                                                     PCT           Published as WO 00/47281
              Heat Pipe)                                                     Application   on August 17, 2000
                                                                             US00/03226
              Microwave
              Devices for                                                    February 8,
              Medical                                                        2000
              Hyperthermia
              Thermotherapy
              and Diagnosis
              (Microwave
              Heat Pipe)
------------- ---------------- --------------------------------------------- ------------- ---------------------------
05785-        Microwave        A medical instrument having a collinear       09/248,168    Issued as U. S. Patent
006001        Systems for      array of antennas used to precisely focus                   No. 6,097,985 on August 1,
              Medical electromagnetic (EM) energy to a desired February 9,                 2000
               Hyperthermia, area of tissue. The medical instrument 1999
              Thermotherapy includes an EM source for providing the EM and
              Diagnosis energy individually to each of the antennas
05785-        (3D Microwave    at a selected amplitude and phase
006WO1        Antenna System)  characteristic.                               PCT           Published as WO 00/47283
                                                                             Application   on August 17, 2000
              Microwave                                                      US00/03451
              Systems for
              Medical                                                        February 9,
              Hyperthermia,                                                  2000
              Thermotherapy
              and Diagnosis
              (3D Microwave
              Antenna System)
------------- ---------------- --------------------------------------------- ------------- ---------------------------
05785-        Microwave        Relates to a unique antenna structure         09/248,170    Issue Fee paid March 20,
011001        Antenna for      having an outer helical winding surrounding                 2001.
              Medical          an inner antenna (e.g., a dipole antenna).    February 9,   Awaiting Letters Patent
              Hyperthermia,                                                  1999
              Thermotherapy    It is important to note that, with the
              and Diagnosis    005001, 006001, and 011001 applications
              (Helical         were filed on the same day.
              Antenna)
                               The specifications of each application were
                               virtually identical.

                               This approach allowed us to file claims covering
                               various combinations of the concepts described in
                               the individual applications. For example,
                               collinear array arrangements for diagnostic
                               imaging and
                               structured as heat pipes are covered.
------------- ---------------- --------------------------------------------- ------------- ---------------------------
</TABLE>

                                       16
<PAGE>

<TABLE>
<CAPTION>
------------- ---------------- --------------------------------------------- ------------- ---------------------------
Matter        Application      Subject Matter                                Serial No.    Status
Number        Name                                                           Filing Date
------------- ---------------- --------------------------------------------- ------------- ---------------------------
<S>           <C>              <C>                                           <C>            <C>
05785-011WO1                   Similarly, methods of treating the prostate
                               including using a pair of antennas, one of    PCT           Published as WO 00/47282
              Medical          which is configures as a helical antenna      Application   on August 17, 2000
              Hyperthermia,    are covered as well.                          US00/03340
              Thermotherapy
              and Diagnosis                                                  February 9,
              (Helical                                                       2000
              Antenna)
------------- ---------------- --------------------------------------------- ------------- ---------------------------
05785-        Heat Pipe Array  An array of antennas for providing            09/377,458    All claims (1-54)
014001                         increased uniformity of radiated microwave                  allowed.  Issue fee due
                               energy into a tissue mass (e.g., tumor).      August 19,    June, 2001
                                                                             1999
------------- ---------------- --------------------------------------------- ------------- ---------------------------
05785-        Microwave        A microwave diagnostic system composed of a   Unfiled       In progress
017001        Diagnostics      collection of electromagnetic source
                               antennas capable of propagating microwave
                               frequency radiation into the human body.
                               Electrical and magnetic impedance tomography
                               concepts are used in conjunction with microwave
                               energy to characterize thermal patterns
------------- ---------------- --------------------------------------------- ------------- ---------------------------
05785-        Microwave        A medical catheter (e.g. Foley) has a         Unfiled       In progress
019001        Catheter         section with an expanded diameter within
                               which a radiating antenna is positioned.
                               The expanded diameter also holds a
                               dielectric fluid (e.g., water) which forms
                               a resonant cavity to provide optimum
                               transmission characteristics.
------------- ---------------- --------------------------------------------- ------------- ---------------------------
</TABLE>

                                       17Exhibit 10.11

                                LICENSE AGREEMENT

This Agreement is made and entered into this 13th day of July, 2001 (the
"Effective Date") by and between Rensselaer Polytechnic Institute, ("RPI"), with
its principal office located at 114 Eighth Street, Troy, New York 12180, and Pro
Uro Care ("PUC") with its principal office located at 15250 Wayzata Blvd., Suite
147, Wayzata, Minnesota 55391.

PREMISES:

WHEREAS RPI is the owner of certain INTELLECTUAL PROPERTY RIGHTS related to
Electrical Impedance Tomography (*,"TECHNOLOGY"); and

WHEREAS R.PI has the right to grant Licenses of said INTELLECTUAL PROPERTY
RIGHTS; and

WHEREAS said INTELLECTUAL PROPERTY RIGHTS are protected and/or protectable by
patents and/or copyrights; and

WHEREAS RPI desires to have the INTELLECTUAL PROPERTY RIGHTS developed and
commercialized to benefit the public and is willing to grant a license thereto;
and

WHEREAS PUC is experienced in the development and commercialization of the
TECHNOLOGY and/or use, manufacture, and sale of products similar to or relating
to the TECHNOLOGY; and

WHEREAS PUC desires to obtain a license of the INTELLECTUAL PROPERTY RIGHTS upon
the terms and conditions hereinafter set forth; and

WHEREAS RPI and PUC wish to cooperate to develop a thorough, vigorous, and
diligent program of exploiting the INTELLECTUAL PROPERTY RIGHTS so that public
utilization as well as GROSS SALES shall result therefrom.

NOW, THEREFORE in consideration of the premises and the mutual covenants
contained herein, the parties hereto agree as follows:

Article 1 Definitions

For the purposes of this Agreement, the following words and phrases shall have
the following meanings

1.1 LICENSOR shall mean RPI.

                                       1
<PAGE>

1.2 LICENSEE shall mean PUC.

1.3 TERRITORY shall mean the world.

1.4 FIELD OF USE shall mean diagnosis and/or treatment of urological conditions.

1.5 PATENT RIGHTS shall mean issued United States Patents listed in Appendix I
and/or Applications for Letters Patent of the United States for the TECHNOLOGY
or portions thereof which have been or which at any time while this Agreement is
in effect shall be fled, including Patents and/or Applications as a substitute
for, or a division, or a continuation, or (to the extent Licensor shall be free
to do so) a continuation-in-part of any of the Patents and/or Applications for
Letters Patent, together with any Letters Patent of the United States (including
any reissues thereof) which may issue on the TECHNOLOGY or portions thereof, and
the issued Patents and/or Applications for Letters Patent of countries other
than the United States corresponding to any of the Letter Patent or Applications
for Letters Patent of the United States enumerated or described above .

1.6 IN'T'ELLECTUAL PROPERTY RIGHTS shall mean PATENT RIGHTS, and all other
rights in any technical information, know-how, process, procedure, composition,
device, method, formula, protocol, technique, software, design, drawings or data
relating to the TECHNOLOGY which are not covered by such PATENT RIGHTS but which
are necessary for practicing the claims of the PATENT RIGHTS.

1.7 LICENSED PROCESS(ES) shall mean any process, which in the course of being
used infringes on one or more claims contained in the INTELLECTUAL PROPERTY
RIGHTS that have not been held invalid by an unappealable judgment of a court or
any other body whatsoever (including the U.S. Patent and Trademark Office) of
competent jurisdiction.

1.8 LICENSED PRODUCT(S) shall mean any product which, in the course of
manufacture, use or sale, would infringe on one or more claims contained in the
INTELLECTUAL PROPERTY RIGHTS that have not been held invalid by an unappealable
judgment of a court or any other body whatsoever (including the U.S. Patent and
Trademark Office) of competent jurisdiction, or which is made using LICENSED
PROCESSES.

1.9 GROSS SALES shall mean revenues received by LICENSEE in consideration for
the sale, transfer or disposition of LICENSED PROCESS(ES) or LICENSED PRODUCTS).

1.10 NET SALES shall mean GROSS SALES less discounts and freight charges.

1.11 RESEARCH & DEVELOPMENT shall be conducted under a separate agreement
between PUC and RPI to combine PATENT RIGHTS with PUC microwave treatment
technology and (a) develop prototype ACT III system for appropriate geometries
and applications, (b) develop software to make images in appropriate geometries
and applications, and (c) conduct lab studies to validate system.

                                       2
<PAGE>

Article 2 - License
2.1 LICENSOR hereby grants to LICENSEE, and LICENSEE hereby accepts subject to
all of the terms and conditions of this Agreement, a royalty-bearing, exclusive
License in the TERRITORY of the INTELLECTUAL PROPERTY RIGHTS, to manufacture,
have manufactured, and/or sell LICENSED PRODUCT(S) and/or LICENSED PROCESS(ES)
for the FIELD OF USE.

2.2 LICENSOR retains the right to use the INTELLECTUAL PROPERTY RIGHTS for
research, development and educational purposes.

Article 3 - Reports & Records

3.1 LICENSEE shall keep full, true and accurate books of account containing all
particulars that may be necessary for the purpose of showing the royalties
payable to LICENSOR as aforesaid. LICENSEE shall permit a representative of
LICENSOR or an independent accountant or accountant firm identified by LICENSOR
to inspect such books of account for the purpose of verifying LICENSEE' S
royalty statements or compliance in other respects with this Agreement. Such
inspections shall be conducted on business days between 9:00 a.m. to 4:00 p.m.,
and shall be agreed upon five (5) days in advance between the parties hereto.

3.2 Within thirty (30) days after June 30 and December 31 of each year, LICENSEE
shall deliver to LICENSOR true and accurate reports, giving such particulars of
the business conducted by LICENSEE during the preceding six-month period under
this Agreement as shall be pertinent to commercialization and royalty accounting
hereunder. Such reports shall include, at least, the following:

      3.2.1 the total numbers of LICENSED PRODUCT(S) and products of LICENSED
      PROCESS(ES) produced by LICENSEE;

      3.2.2 GROSS SALES;

      3.2.3 the amount of royalties payable;

      3.2.4 such other information (if any) as may be necessary to show the
      basis on which the amount of royalties has been computed.

Article 4 - Obligations of LICENSOR and LICENSEE

4.1 LICENSOR and LICENSEE desire that the LICENSED PRODUCT(S) and/or LICENSED
PROCESS(ES) be commercialized in the TERRITORY through a thorough, vigorous and
diligent program for exploitation of the INTELLECTUAL PROPERTY RIGHTS.

4.2 LICENSOR shall cooperate with LICENSEE' S commercialization effort by:

                                       3
<PAGE>

      4.2.1 providing within a reasonable time of request such technical
      information, know-how, process, procedure, composition, device, method,
      formula, protocol, technique, software, design, drawing or data relating
      to INTELLECTUAL PROPERTY RIGHTS in its possession which are necessary for
      practicing the claims of the PATENT RIGHTS; and

      4.2.2 advising LICENSEE of any developments or improvements to the
      INTELLECTUAL PROPERTY RIGHTS from RESEARCH & DEVELOPMENT; and

      4.2.3 continuing with maintenance of PATENT RIGHTS.

4.3 LICENSEE shall meet the following milestones in order to maintain the
exclusive License, otherwise the License becomes non-exclusive:

      4.3.1 initiate FDA approval process by five (5) years from Effective Date
      of this Agreement; and

      4.3.2 pay LICENSOR minimum royalties of $20,000 per year after four (4)
      years from Effective Date of this Agreement.

Article 5 - Royalties and Consideration

      5.1 In consideration of the rights granted by LICENSOR hereunder, LICENSEE
      shall:

      5.1.1 pay LICENSOR $50,000 in two installments: $25,000 by July 1, 2002
      and $25,000 by July 1, 2003.

      5.1.2 pay LICENSOR royalties of 3% of NET SALES of LICENSED PRODUCTS, one
      of the primary functions of which is tomography, and 1% of NET SALES of
      LICENSED PRODUCTS, the primary function of which is not tomography, but
      needs tomography to function.

Article 6 - Technical Cooperation

6.1 All improvements to the TECHNOLOGY from RESEARCH & DEVELOPEMENT, including
technical information, know-how, and inventions whether patentable or not,
relating to INTELLECTUAL PROPERTY RIGHTS, created or developed solely by
LICENSOR, including all patents and patent applications, shall be owned by
LICENSOR and shall be part of the INTELLECTUAL PROPERTY RIGHTS.

6.2 All improvements to the TECHNOLOGY from RESEARCH & DEVELOPMENT, including
technical information, know-how, and inventions whether patentable or not,
relating to INTELLECTUAL PROPERTY RIGHTS, created or developed solely by
LICENSEE, including all patents and patent applications, shall be owned by
LICENSEE, and LICENSEE hereby grants LICENSOR an irrevocable, non-exclusive,
non-transferrable License to such rights solely for research, development and
educational purposes.

                                       4
<PAGE>

6.3 All improvements to the TECHNOLOGY from RESEARCH & DEVELOEMENT, including
technical information, know-how, and inventions whether patentable or not,
relating to INTELLECTUAL PROPERTY RIGHTS, created or developed jointly by
LICENSOR and LICENSEE, including all patents and patent applications, shall be
jointly owned by LICENSOR and LICENSEE, and LICENSOR'S rights shall be part of
the INTELLECTUAL PROPERTY RIGHTS, and LICENSEE hereby grants LICENSOR an
irrevocable, non-exclusive, non-transferrable License to LICENSEE'S rights
solely for research, development and educational purposes .

Article 7 - Confidentiality

7.1 LICENSOR and LICENSEE acknowledge that much of the information which may be
exchanged pursuant to this Agreement will be confidential and proprietary in
nature. Each agrees that all information disclosed hereunder shall be
safeguarded by the recipient thereof, shall not be disclosed to third parties,
and shall be made available only to employees, independent contractors, and
agents of the recipient who agree in writing to be bound by the provisions of
this Article 7. l. Such information shall remain the property of and be returned
to the disclosing party within thirty (30) days of a request by the disclosing
party, or, if not so, requested, then within thirty (30) days of the termination
of this Agreement.

7.2 The provisions of Article 7.1 shall not apply to information that:

      7.2.1 is or hereafter becomes generally available to the public, other
      than by reason of a breach of the provisions of Article 7.1;

      7.2.2 was already known to the recipient as evidenced by prior written
      documents in its possession;

      7.2.3 is disclosed to the recipient by a third party who is not in default
      of any confidentiality, obligation to the disclosing party hereunder;

      7.2.4 is developed by or on behalf of the receiving party without reliance
      on information received hereunder;

      7.2.5 is provided to third parties under appropriate terms and conditions,
      including confidentiality provisions equivalent to those in this Agreement
      for consulting, manufacturing, and marketing with respect to LICENSED
      PRODUCTS and/or LICENSED PROCESSES, provided, however, that the
      information so provided shall remain confidential and subject to the
      provisions of Article 7.1;

                                       5
<PAGE>

      7.2.6 is used with the consent of the disclosing party (which consent
      shall not be unreasonably withheld) in applications for patents or
      copyrights under the terms of this Agreement, provided, however, that the
      information so provided shall remain confidential and subject to the
      provisions of Article 7.1;

      7.2.7 has been approved for publication in writing by both LICENSOR and
      LICENSEE;

      7.2.8 is required to be disclosed in compliance with applicable laws or
      regulations in connection with the manufacture or sale of LICENSED
      PRODUCTS and/or use of LICENSED PROCESSES; or

      7.2.9 is otherwise required to be disclosed in compliance with applicable
      laws or regulations or order by a court or other regulatory body having
      competent jurisdiction.

7.3 The provisions of Article 7.1 shall apply for a period of three (3) years
following the termination of this Agreement.

Article 8 - Infringement or other violation of INTELLECTUAL PROPERTY RIGHTS

8.1 Each party shall promptly notify the other in writing of any discovered
infringement or other violation of INTELLECTUAL PROPERTY RIGHTS or suspected
infringement or other violation of INTELLECTUAL PROPERTY RIGHTS of valid claims
contained in the INTELLECTUAL PROPERTY RIGHTS; and the parties shall discuss the
course of action to pursue. LICENSEE shall have the first option of commencing
litigation at its sole expense to. enforce the said claims against infringement
or other violation of INTELLECTUAL PROPERTY RIGHTS, If LICENSEE, within ninety
(90) days of either receiving written notice, or otherwise personally learning,
of infringement or other violation of INTELLECTUAL PROPERTY RIGHTS or suspected
infringement or other violation of INTELLECTUAL PROPERTY RIGHTS, has (i) not,
commenced such litigation, or (ii) if having so commenced shall thereafter not
pursue such litigation, then LICENSOR shall have the option of doing so, at its
own expense.

8.2 Any recovery of monetary damages as a result of litigation shall be for the
account of the party that actively pursued such litigation.

8.3 Where either party pursues such litigation hereunder, the other agrees to
provide requested technical advice and testimony and other reasonably requested
assistance at no cost to the other.

8.4 In the event that a claim or suit is asserted or brought against LICENSEE on
account of its practice of any rights granted thereunder, and the basis of such
claim or suit is that the technologies defined by the INTELLECTUAL PROPERTY
RIGHTS have infringed another U.S. or other country patent or any other
intellectual property right, LICENSEE shall promptly notify LICENSOR of such
claim or suit. LICENSOR shall have the option of defending such action or the
discretion of taking whatever actions it considers necessary to uphold its
rights. Should LICENSOR elect not to defend or take any action, LICENSEE shall
have the option of doing so with all costs and expenses incurred by either party
paid by that party.

                                       6
<PAGE>

8.5 In any event, should LICENSOR not have control of a proceeding or action in
which LICENSEE is engaged pertaining to infringement or other violation of
INTELLECTUAL PROPERTY RIGHTS, and settlement would impose liability on LICENSOR,
or affect validity or enforcement of INTELLECTUAL PROPERTY RIGHTS, then there
shall be no settlement of such claim or suit at any time absent consultation
with and approval by LICENSOR. Should LICENSOR refuse to consent to a proposed
settlement desired by LICENSEE, LICENSOR shall then be responsible for
reasonable continuing costs of litigation.

8.6 In the event a settlement or adjudication of such claim or suit results in
the payment of royalties by LICENSEE, and/or in the event a License is purchased
by LICENSEE in resolution of such infringement or other violation of
INTELLECTUAL PROPERTY RIGHTS claim, the amount of any royalties or license fee
paid by LICENSEE to such third party will be offset against the amount of
royalties and/or other consideration due to LICENSOR according to Article 5.

8.7 In the event that the INTELLECTUAL PROPERTY RIGHTS are deemed invalid or
unenforceable by final judgment or decree, LICENSEE shall have the right to use
the INTELLECTUAL PROPERTY RIGHTS without further obligation of LICENSEE, but
also without any further rights to the License granted by this Agreement.

Article 9 - Term and Termination

9.1 The term of this Agreement shall commence on the Effective Date and shall
expire concurrently with the expiration, invalidation, or lapsing of all pending
or issued patents within the PATENT RIGHTS and the abandonment of all pending
patent applications within the PATENT RIGHTS.

9.2 The term of this Agreement shall terminate if no LICENSED PROCESS or
LICENSED PRODUCT is available for sale after five (5) years from Effective Date.

9.3 If LICENSEE shall cease to carry on its business, this Agreement shall
terminate immediately without any action required, but all obligations of
LICENSEE to LICENSOR shall survive, and LICENSOR shall be entitled to an
immediate assignment of any sublicenses hereunder.

9.4 If this Agreement is terminated for any reason, LICENSEE shall for a period
of five (5) years from the date of termination not market any product, or grant
a license to market any product that would compete with a LICENSED PRODUCT or
LICENCED PROCESS, with the exception of pressure-based digital rectal exam
system by LICENSEE. If the event that LICENSEE shall breach this provision,
LICENSOR shall in addition to an injunction, be entitled to royalties on all
such revenues received in accordance with the provisions of this Agreement.

                                       7
<PAGE>

Article 10 - Representations, Warranties and Covenants

10.1 LICENSOR represents, warrants and covenants to LICENSEE as follows:

      10.1.1 LICENSOR has good title to the INTELLECTUAL PROPERTY RIGHTS, which
      are free and clear of all liens and encumbrances and have not been
      licensed to any third party.

      10.1.2 LICENSOR has no knowledge of anything that would lead it to believe
      that any rights licensed hereunder violate proprietary rights of others,
      nor has LICENSOR received notice from any third parry claiming that a
      license must be obtained from such parry in connection with use of any
      rights licensed hereunder.

      10.1.3 Except for the foregoing warranties, LICENSOR expressly disclaims
      all warranties, express or implied, including without limitation
      warranties of merchantability, fitness for a particular purpose,
      usefulness for any purpose, health and safety risks, or freedom from
      infringement or other violation of INTELLECTUAL PROPERTY RIGHTS of patents
      or other proprietary rights of others with respect to the License granted
      herein.

10.2 LICENSEE represents, warrants and covenants to LICENSOR as follows:

      10.2.1 LICENSEE is a corporation duly incorporated, validly existing and
      in good standing under the laws of Minnesota and is duly licensed or
      qualified to transact business as a corporation in good standing in New
      York State and in all jurisdictions in which its ownership or leasing of
      property or the conduct of its business requires such qualification.
      LICENSEE has the corporate power and authority to own and hold its
      properties and to carry on its business as now conducted and as proposed
      to be conducted, and to, execute, deliver and perform this Agreement. The
      execution and delivery by LICENSEE of this Agreement and the performance
      by LICENSEE of its obligations hereunder have been duly authorized by all
      requisite corporate action.

      10.2.2 The employees, agents and consultants of LICENSEE with relationship
      to this Agreement are obligated and to the best of LICENSEES knowledge
      have signed agreements or are otherwise obligated to assign all
      intellectual property, including patents and patent applications to
      LICENSEE and to maintain any confidential information in confidence.

      10.2.3 LICENSEE and its representatives have had full opportunity to
      review the INTELLECTUAL PROPERTY RIGHTS and to make all desired inquiries
      and receive satisfactory answers related thereto.

                                       8
<PAGE>

      10.2.4 LICENSEE shall at all times during the term of this Agreement and
      thereafter indemnify, defend, and hold LICENSOR, its trustees, directors,
      officers, employees and affiliates harmless against all claims,
      proceedings, demands and liabilities of any kind whatsoever, including
      legal expenses and, reasonable attorneys' fees, arising out of the death
      of or injury to any person or persons or out of any damage to property, or
      resulting from the production, manufacture, sale, use, lease, consumption
      or, advertisement of LICENSED PRODUCT(S), products of LICENSED PROCESS(ES)
      and/or LICENSED PROCESS(ES) or arising from any, obligation of LICENSEE
      hereunder, excepting only claims that the INTELLECTUAL PROPERTY RIGHTS
      infringe third party intellectual property.

Article I 1 - Arbitration Clause

11.1 All disputes, where the amount claimed is less than $100,000.00 arising out
of or in connection with this Agreement, including any issue as to this
Agreement's validity or enforceability, which cannot be settled amicably between
the parties, shall be finally settled by arbitration in accordance with the
Rules of the American Arbitration Association by an arbitration tribunal of
three arbitrators. All other disputes shall not be subject to Arbitration. It is
expressly understood and agreed that any dispute as to the arbitrability of any
claim under this Agreement, including whether the party has asserted claims in
excess of the monetary limits set forth herein, shall be determined by a Court
of competent jurisdiction and shall not be determined by the arbitrators.

11.2 The place of the arbitration shall be Troy, New York.

Article 12 - Notices

All notices and other communications in connection with this Agreement shall be
in writing and shall be sent to the respective parties at the following
addresses, or to such other addresses as may be designated by the parties in
writing from time to time by registered or certified mail, telegram, telex,
express delivery service or facsimile.

TO LICENSOR:

Charles F. Rancourt, Director
Office of Technology Commercialization
J Building Room 3210
Rensselaer Polytechnic Institute
Troy, New York 12180
Fax No. (518) 276-6380

                                       9
<PAGE>

TO LICENSEE:

David Koenig, President
Pro Uro Care
15250 Wayzata Blvd., Suite 107,
Wayzata, Minnesota 55391

Article 13 - General Provisions

13.1 Governing Law: This Agreement shall be governed by, construed and enforced
in accordance with the laws of New York State and any action brought regarding
or arising out of this Agreement shall be in Federal Court, Northern District of
New York (Albany), or New York State Supreme Court, Rensselaer County.

13.2 Severability: If any provision of this Agreement shall be declared void or
unenforceable by any judicial or administrative authority, the validity of any
other provision or of the entire Agreement shall not be affected thereby, but
this Agreement shall be reformed to eliminate such provision, unless such
provision shall be so significant as to materially affect this Agreement, in
which case the parties agree to replace such invalid provision with a valid
provision which most closely approximates the intent and economic effect of the
invalid provision.

13.3 The failure of either party to assert a right hereunder or to insist upon
compliance with any term or condition of this Agreement shall not constitute a
waiver of that right or excuse a similar subsequent failure to perform any such
term or condition by the other party.

13.4 Publicity: Subject to any mutually agreed upon press release, each party
hereto agrees not to disclose the substantive terms and conditions of this
Agreement, which shall be considered a confidential proprietary document of each
ply, except as may be: (i) with prior written notice: (ii) provided m this
Agreement; (iii) required by law of government rule or regulation, or (iv)
required far financing or commercial purposes (but, then only in confidence).
Notwithstanding the foregoing, any disclosure of the substantive terns of this
Agreement may occur only after a party has received the express written consent
of the other. Any publicity or press release concerning the transactions
provided for in this Agreement shall be jointly planned and coordinated by the
parties.

13.5 Neither party, absent written approval of the other, shall have any right
to use the name, trade name, or trademark of the other.

13.6 Neither party, absent written approval of the other, shall assign any
rights under this Agreement to any third party.

13.7 This Agreement shall be binding upon and inure to the benefit of LICENSOR
and LICENSEE and their respective successors and assigns.

13.8 Force Majeure: If the performance of this Agreement or any obligations
hereunder, is prevented, restricted or interfered with by reason of fire, flood,
explosion, or other casualty, accident, or act of God; strikes or labor
disturbances; war, whether declared or not, or other violence; sabotage; any
law, order, proclamation, regulation, ordinance, demand or requirement of any
government agency; or any other event, beyond the reasonable control of a party
and without its fault or negligence, the affected partly, upon giving prompt
notice to the other party, shall be excused from such performance to the extent
of such prevention restriction or interference. The affected party shall use its
reasonable efforts to avoid or remove such cause of non-performance or to limit
the impact of the event on such party=s performance, and shall continue
performance with the utmost dispatch whenever such causes are removed.

                                       10
<PAGE>

13.9 This Agreement, with respect to the subject matter hereof, (i) contains the
entire understanding between, LICENSOR and LICENSEE, (ii)supersedes all prior
agreements with respect to the subject matter, and (iii), may only he amended by
another writing signed by both LICENSOR and LICENSEE.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
by their duly authorized officers as of the date first above written.

RENSSELAER POLYTECHNIC INSTITUTE

By: Charles Rancourt                        By: Arthur Sanderson
    ------------------------------              --------------------------
    Charles F. Rancourt                         Arthur Sanderson
    Director, Office of Technology              Vice President, Research
    Commercialization

PRO URO CARE

By: Maury Taylor
    -----------------------------
Maurice Taylor
Title: President
       --------------------------

                                       11
<PAGE>

The following, by signing acknowledge that they have reviewed and agree to the
terms of this Agreement.

By: David Isaacson                                   By: Jonathan C. Newell
   ----------------------------------                   ------------------------
David Isaacson                                       Jonathan C. Newell
Inventor                                             Inventor

Date:                                                 Date:
     --------------------------------                      ---------------------

By: Gary J. Saulnier
   ----------------------------------
Gary J. Saulnier
Inventor

Date:
     ---------------------------------

                                       12
<PAGE>

APPENDIX I - Patents

US Patent No. 4,920,490, "Process and Apparatus for Distinguishing
Conductivities by Electric Current Computed Tomography", issued April 24,1990;
and

US Patent No. 5,272,624, "Current Patterns for Impedance Tomography", issued
December 21, 1993; and

US Patent No. 5,284,142, "Three-Dimensional Impedance Imaging Processes", issued
February 8, 1994; and

US Patent No. 5,351,697, "Three-Dimensional Impedance Imaging Process", issued
October 4, 1994; and

US Patent No. 5,381,333, "Current Patterns for Electrical Impedance Tomography",
issued January 10,1995; and

US Patent No. 5,390,110, "Layer Stripping Process for Impedance Imaging", issued
February 14, 1995; and

US Patent No. 5,544,662, "High-Speed Electric Tomography", issued August
13,1996; and

US Patent No. 5,588,429, "Process for Producing Optimal Current Patterns for
Electrical Impedance Tomography", issued December 31, 1996.

                                       13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}]]